Business Context and Reporting Period
Regeneron Pharmaceuticals, Inc. filed its Form 10-K for the fiscal year ended December 31, 2014. The company is an integrated biopharmaceutical developer, manufacturer, and commercializer operating as one segment. Its marketed products were EYLEA for ophthalmic diseases, ZALTRAP for metastatic colorectal cancer, and ARCALYST for CAPS.
Although the request references 2014 Q4, this filing is an annual report. Fourth-quarter 2014 revenue was $802.3 million and net income was $110.2 million, compared with fourth-quarter 2013 revenue of $610.4 million and net income of $96.8 million.
Financial Performance and Position
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Total revenue | $2,819.6 million | $2,104.7 million | 34.0% increase |
| Net product sales | $1,750.8 million | $1,425.8 million | 22.8% increase |
| Collaboration revenue | $1,036.9 million | $650.4 million | 59.4% increase |
| Income from operations | $838.4 million | $760.0 million | 10.3% increase |
| Operating margin | 29.7% | 36.1% | Decreased |
| Net income | $348.1 million | $424.4 million | 18.0% decrease |
| Diluted EPS | $3.07 | $3.81 | 19.4% decrease |
| Net margin | 12.3% | 20.2% | Decreased |
| Operating cash flow | $743.2 million | $583.6 million | 27.3% increase |
| Capital expenditures | $333.0 million | $156.3 million | More than doubled |
EYLEA U.S. net product sales increased to $1,736.4 million from $1,408.7 million. EYLEA sales outside the United States, recorded by Bayer HealthCare, increased to $1,038.5 million from $472.1 million; Regeneron recorded $301.3 million of related net collaboration profit in 2014 versus $101.5 million in 2013. ZALTRAP net product sales recorded by Sanofi increased to $91.4 million from $70.2 million, while ARCALYST sales declined to $14.4 million from $17.1 million.
Research and development expense increased to $1,271.4 million from $859.9 million, and selling, general, and administrative expense increased to $504.8 million from $329.4 million. Total operating expenses rose 47.3%, faster than revenue. Non-cash compensation expense was $307.2 million, compared with $198.4 million in 2013.
As of December 31, 2014, cash and cash equivalents were $648.7 million and marketable securities were $711.9 million, for combined cash, cash equivalents, and marketable securities of $1.36 billion. Total assets were $3.87 billion and stockholders’ equity was $2.54 billion.
Remaining convertible senior note principal was $169.4 million, with a $146.8 million carrying value, due October 1, 2016 unless converted or repurchased. Facility lease obligations were $312.3 million. The filing reports no credit facility or short-term financing arrangement.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven primarily by higher EYLEA volume in the United States and internationally, expanded collaboration activity, and $105.0 million of Bayer HealthCare sales milestones.
- Profit and EPS declined despite higher revenue because of sharply increased research, clinical manufacturing, commercialization, and stock-based compensation costs; higher income tax expense; and a $33.5 million loss on extinguishment of converted debt.
- Net cash from operations increased to $743.2 million, but investing cash use increased to $420.8 million because of manufacturing expansion, the Limerick, Ireland facility, and Tarrytown improvements.
- During 2014, $230.6 million of convertible notes were surrendered for conversion; $220.6 million was settled by year-end. Regeneron also paid $294.6 million to reduce outstanding warrants.
- Rensselaer manufacturing capacity expanded by 20,000 liters and approximately 65,000 square feet. The company acquired a 400,000-square-foot facility in Limerick, Ireland for $5.1 million and began renovations.
- Sanofi and Regeneron began sharing pre-launch commercialization expenses for PRALUENT and sarilumab, resulting in $41.4 million of Regeneron share-of-loss expense for antibody commercialization.
Guidance, Outlook, Commentary, Risks, and Unusual Items
Management stated that existing capital resources, anticipated EYLEA sales, and collaboration funding were expected to support operating needs for the foreseeable future. The company expected continued increases in research and development, commercialization, and capital spending. Capital expenditures for 2015 were estimated at approximately $650 million to $800 million, primarily for Limerick, Tarrytown, Rensselaer, and equipment.
The filing does not provide revenue or earnings guidance. Management emphasized that future profitability and operating cash flow depend significantly on continued EYLEA success, regulatory approvals, product acceptance, reimbursement, competition, manufacturing capacity, and the continuation of the Sanofi and Bayer HealthCare collaborations.
- Pipeline: PRALUENT, sarilumab, and dupilumab were in late-stage development. PRALUENT received FDA priority review, with a target action date of July 24, 2015. Dupilumab received FDA Breakthrough Therapy designation for moderate-to-severe atopic dermatitis.
- Regulatory and clinical risk: REGN1500 and fasinumab were subject to partial FDA clinical holds. Clinical results may not translate into approval or commercial success.
- Patent litigation: Amgen sued Regeneron and Sanofi regarding PRALUENT patents and sought an injunction, damages, and other relief. The filing states that a potential loss could not yet be estimated. Regeneron also faced proceedings involving its antibody-platform patents; a U.S. court held the ’018 patent invalid and non-infringed as to Merus, while the company appealed, and the European ’287 patent was revoked by the EPO opposition division before being reinstated pending appeal.
- Collaboration obligations: contingent reimbursement obligations were approximately $1.30 billion to Sanofi for the antibody collaboration, $461 million to Sanofi for ZALTRAP, and $263 million to Bayer HealthCare for EYLEA.
- Revenue concentration: EYLEA U.S. sales represented 62% of total revenue in 2014. Besse Medical accounted for 73% of total gross product revenue, creating significant customer concentration.
- Tax and unusual items: the effective tax rate was 55.1%, compared with 40.5% in 2013. A $40.6 million incremental Branded Prescription Drug Fee charge was recorded in the third quarter of 2014. The 2012 comparison included a $335.8 million tax benefit from releasing substantially all of the deferred-tax-asset valuation allowance.
- Future cash commitments: contractual obligations totaled $1.34 billion, including $771.1 million of purchase and other obligations, $286.6 million of facility lease obligations, and $175.7 million related to convertible notes. The filing also disclosed $57.6 million of unrecognized tax benefits.
Important Facts for Investors to Verify
- Whether EYLEA volume, pricing, reimbursement, and competitive dynamics can sustain growth and offset the company’s high concentration in one product.
- The timing and outcome of FDA and international decisions for PRALUENT, EYLEA diabetic retinopathy, sarilumab, dupilumab, and other pipeline programs.
- The potential financial and commercial impact of Amgen’s PRALUENT patent litigation and the company’s other patent proceedings.
- Whether the Limerick and Rensselaer manufacturing expansions are completed on budget and on schedule, including the disclosed 2015 capital expenditure plan.
- The extent to which collaboration reimbursements, milestones, profit sharing, and contingent repayment obligations affect recurring revenue and cash flow.
- The sustainability of profitability after excluding milestone revenue, non-cash stock compensation, debt-conversion effects, and other unusual items.
- The effect of the 55.1% effective tax rate, expiration or extension of research tax credits, foreign losses, and uncertain tax positions on future cash taxes.
- Potential dilution or cash requirements from the remaining convertible notes and warrants, including the disclosed 2015 warrant payments.